To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Impaired Glucose Tolerance

Interventions

DRUG: Canakinumab 150 mg
DRUG: Placebo to Canakinumab

Sponsor

Novartis